Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.07K$17.07Kderivedno prior Q4 2018 on file Net Income-$1.17M-$1.17MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,234,854N/M Operating Cash Flowderived-$1,677,752N/M Margins · derivedOperating margin-7235.8%
Net margin-6857.2%
ended Dec 31, 2019 · filed Mar 26, 2020 · 86 d after period end